Document Detail


The efficacy and safety of antidepressants in inflammatory arthritis: a cochrane systematic review.
MedLine Citation:
PMID:  22942325     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
METHODS: We searched the Cochrane Central Register of Controlled Trials, Medline, Embase, and PsychINFO for randomized controlled trials in adults with IA that compared any antidepressants (administered via any route) to another analgesic intervention or placebo. We also searched the 2008-2009 American College of Rheumatology and European League Against Rheumatism abstracts and performed a hand search of reference lists of relevant articles. Primary outcomes were patient-reported pain relief ≥ 30% and withdrawals due to adverse events. Two authors independently assessed methodological quality and extracted data. A risk of bias assessment was performed using methods recommended by the Cochrane Collaboration.
RESULTS: Eight trials (652 participants) in patients with rheumatoid arthritis (RA) and 1 trial in patients with ankylosing spondylitis (100 participants) were included in this review. The majority of studies were published in the late 1980s in patients with active disease receiving minimal disease-modifying antirheumatic drug therapy. All trials evaluated tricyclic antidepressants (TCA) and 2 studies included a selective serotonin uptake inhibitor. Seven of the 9 trials had high risk of bias, 2 were unclear, and metaanalysis was not performed due to trial heterogeneity. RA trials with short-term outcome (< 1 week) found no significant benefit of amitriptyline 25 mg in combination with dextropropoxyphene (DXP) 65 mg over placebo, and inferiority of amitriptyline + DXP versus DXP 130 mg [mean difference (MD) 10.0, 95% CI 0.4 to 19.6]. There was conflicting evidence regarding medium (1-6 wks) or longer-term (> 6 wks) benefits on pain. One trial in depressed patients with RA showed no significant difference between amitriptyline and paroxetine given for 8 weeks (65% vs 56% much or very much improved; RR 1.2, 95% CI 0.9 to 1.5). One trial found that amitriptyline was no better than placebo in reducing pain in patients with active AS over 2 weeks (MD -0.2, 95% CI -1.2 to 0.8). From 5 trials, withdrawals due to adverse events were not significantly different from placebo. However, there were significantly more minor adverse events in patients receiving TCA compared with those receiving a placebo (RR 2.3, 95% CI 1.2 to 4.4). These included somnolence, dizziness, dry mouth, and nausea.
CONCLUSION: Based upon 9 trials of high or unclear risk of bias, it is not possible to draw firm conclusions about the efficacy of TCA as analgesics for patients with IA. The use of these agents may be associated with adverse events that are generally mild and do not lead to cessation of treatment. High-quality trials are needed in this area.
Authors:
Bethan L Richards; Samuel L Whittle; Désirée M van der Heijde; Rachelle Buchbinder
Related Documents :
24824425 - Clinical decision making in the treatment of mixed states.
24990645 - Are recommendations for psychological treatment of borderline personality disorder in c...
24187615 - Prevalence of depression among university students: a systematic review and meta-analys...
23432795 - Periodontitis and chronic kidney disease: a systematic review of the association of dis...
22869885 - Randomized phase ii trial designs with biomarkers.
15094255 - A comparison of the phenomenology and treatment of youths and adults with bipolar i dis...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The Journal of rheumatology. Supplement     Volume:  90     ISSN:  0380-0903     ISO Abbreviation:  J Rheumatol Suppl     Publication Date:  2012 Sep 
Date Detail:
Created Date:  2012-09-03     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7806058     Medline TA:  J Rheumatol Suppl     Country:  Canada    
Other Details:
Languages:  eng     Pagination:  21-7     Citation Subset:  IM    
Affiliation:
Address correspondence to Dr. B.L. Richards, Department of Rheumatology, Royal Prince Alfred Hospital, Level 4 QEII Building, Missenden Road, Camperdown NSW 2110, Australia., E-mail: brichard@med.usyd.edu.au.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The role of corticosteroids for pain relief in persistent pain of inflammatory arthritis: a systemat...
Next Document:  Efficacy and safety of neuromodulators in inflammatory arthritis: a cochrane systematic review.